Ikarian Capital, LLC Monte Rosa Therapeutics, Inc. Transaction History
Ikarian Capital, LLC
- $714 Million
- Q1 2025
A detailed history of Ikarian Capital, LLC transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 136,575 shares of GLUE stock, worth $542,202. This represents 0.09% of its overall portfolio holdings.
Number of Shares
136,575
Previous 311,575
56.17%
Holding current value
$542,202
Previous $2.16 Million
70.72%
% of portfolio
0.09%
Previous 0.36%
Shares
3 transactions
Others Institutions Holding GLUE
# of Institutions
108Shares Held
53.4MCall Options Held
69.1KPut Options Held
22.4K-
Nea Management Company, LLC Timonium, MD7.69MShares$30.5 Million3.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.64MShares$26.4 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA5.66MShares$22.5 Million1.15% of portfolio
-
Versant Venture Management, LLC San Francisco, CA5.65MShares$22.4 Million54.61% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$19.5 Million0.27% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $185M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...